Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Bjorg Thorsteinsdottir, MD, Annika Beck, and Jon C. Tilburt, MD, MPH
Good clinicians understand why a patient is asking for a test or treatment, and their skillful counseling can often stem the tide of requests for marginally beneficial tests and procedures.
AMA J Ethics. 2015;17(11):1028-1034. doi:
10.1001/journalofethics.2015.17.11.ecas2-1511.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
A nudge is an intervention designed to prompt a person to “voluntarily” make a choice intended by those who altered an environment or situation to yield that choice.
AMA J Ethics. 2020;22(9):E767-772. doi:
10.1001/amajethics.2020.767.